Clinical Development of the First Objective Test for Attention Deficit Disorder Could Help Resolve the Ritalin Debate.Business Editors and Health/Medical Writers BIOWIRE2K BOSTON--(BW HealthWire)--March 21, 2000 Experts Available for Interviews; Video News Release Feed on Tuesday Morning Hillary Rodham Clinton announced a federal program Monday to caution parents about giving children Ritalin and other psychiatric drugs meant to treat attention deficit disorders. In the past 10 years, there has been a 700 percent increase in the use of potent psychostimulants, like Ritalin, among young children. However, no objective diagnostic test for attention deficit/hyperactivity disorder Attention deficit/hyperactivity disorder A persistent pattern of inattention, hyperactivity and/or impulsiveness; the pattern is more frequent and severe than is typically observed in people at a similar level of development. (ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or ) currently exists. Research published recently in The Lancet reports that a radio-imaging agent called Altropane(TM) shows promise as potentially the first objective diagnostic test for ADD/ADHD. The test, which identifies and measures brain biochemical abnormalities specific to patients with ADHD, could eliminate the guesswork currently used to diagnose the disorder. The following experts are available to comment on the clinical development of Altropane: -- Bertha K. Madras, Ph.D., professor of psychobiology psychobiology /psy·cho·bi·ol·o·gy/ (-bi-ol´o-je) 1. biopsychology; a field of study examining the relationship between brain and mind, studying the effect of biological influences on psychological functioning or mental , Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. , whose scientific research served as the basis for Altropane's current development as a diagnostic for ADHD and early Parkinson's Disease. -- Marc Lanser, MD, chief scientific officer of Boston Life Sciences, Inc., (BLSI BLSI Boston Life Sciences, Inc. ) the Company that is developing Altropane. Boston Life Sciences expects to commence Phase II clinical trials for the use of Altropane as a diagnostic for ADHD in the next two to four weeks. A VNR VNR Video News Release VNR Van Nostrand Reinhold (publishing company) VNR Video Noise Reduction VNR Veranstaltungsnummer VNR VFR Flight Not Recommended VNR Video News Reel VNR Very Nice Roll VNR Variable Navigation Ratio IS AVAILABLE FOR FREE AND UNRESTRICTED USE, INCLUDING: Interview with Edward Hallowell, MD, psychiatrist, author of "Driven to Distraction" Interview with Bertha Madras, Ph.D., Harvard Medical School Interview with Susan Gaughan, whose son Danny takes Ritalin for ADD Marc Lanser, MD, chief scientific officer of Boston Life Sciences Dr. Madras in the laboratory Lifestyle video with Danny and Susan Gaughan SATELLITE INFORMATION: ALL COORDINATES ARE ON C-BAND, AUDIO 6.2,6.8 MHz TUESDAY, MARCH 21, 2000: 10:10-10:15 AM EST EST electroshock therapy. EST abbr. electroshock therapy TELSTAR 6, TRANSPONDER 8, DOWNLINK: 3860 MHz Horizontal |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion